What is already known
Phosphodiesterase 5 inhibitors have been highlighted as potentially valuable for preventing colorectal cancer in high-risk individuals.
Conventional phosphodiesterase 5 inhibitors enter the circulation to cause side-effects and drug-drug interactions that reduce their suitability as chemoprevention agents.